BR0200596A - Method of treatment by a combination of a tissue plasminogen activating variant (t-pa) and a low molecular weight heparin and use thereof - Google Patents

Method of treatment by a combination of a tissue plasminogen activating variant (t-pa) and a low molecular weight heparin and use thereof

Info

Publication number
BR0200596A
BR0200596A BR0200596A BR0200596A BR0200596A BR 0200596 A BR0200596 A BR 0200596A BR 0200596 A BR0200596 A BR 0200596A BR 0200596 A BR0200596 A BR 0200596A BR 0200596 A BR0200596 A BR 0200596A
Authority
BR
Brazil
Prior art keywords
treatment
molecular weight
combination
low molecular
tissue plasminogen
Prior art date
Application number
BR0200596A
Other languages
Portuguese (pt)
Inventor
Paul Armstrong
Hal Barron
Silvano Berioli
Frederique Bigonzi
Erich Bluhmki
Richard Chim
Christopher Granger
Frans Van De Werf
Fong Wang-Clow
Original Assignee
Genentech Inc
Aventis Pharm Prod Inc
Boehringer Ingelheim Pharma
Boehringer Ingelheim Italia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Aventis Pharm Prod Inc, Boehringer Ingelheim Pharma, Boehringer Ingelheim Italia filed Critical Genentech Inc
Priority to BR0200596A priority Critical patent/BR0200596A/en
Publication of BR0200596A publication Critical patent/BR0200596A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODO DE TRATAMENTO POR MEIO DE UMA COMBINAçãO DE UMA VARIANTE ATIVADORA DE PLASMINOGêNIO DE TECIDO (t-PA) E UMA HEPARINA DE BAIXO PESO MOLECULAR E USO DA MESMA". A presente invenção refere-se a um regime terapêutico aprimorado para o tratamento de disfunções trombolíticas, tais como infarto agudo do miocárdio (AMI). Particularmente, a presente invenção refere-se ao tratamento de disfunções trombolíticas, tais como AMI, com uma combinação de uma variante ativadora de plasminogênio de tecidos (t-PA) que possui maior especificidade de fibrina e maior meia-vida de plasma em comparação com t-PA humano do tipo selvagem e heparina de baixo peso molecular."METHOD OF TREATMENT THROUGH A COMBINATION OF A TISSUE PLASMINOGEN ACTIVATOR VARIANT (t-PA) AND A LOW MOLECULAR WEIGHT HEPARIN AND USE OF THE SAME". The present invention relates to an improved therapeutic regimen for the treatment of thrombolytic dysfunctions, such as acute myocardial infarction (AMI). Particularly, the present invention relates to the treatment of thrombolytic dysfunctions, such as AMI, with a combination of a tissue plasminogen activating variant (t-PA) that has higher fibrin specificity and longer plasma half-life compared to wild-type human t-PA and low molecular weight heparin.

BR0200596A 2002-02-22 2002-02-22 Method of treatment by a combination of a tissue plasminogen activating variant (t-pa) and a low molecular weight heparin and use thereof BR0200596A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR0200596A BR0200596A (en) 2002-02-22 2002-02-22 Method of treatment by a combination of a tissue plasminogen activating variant (t-pa) and a low molecular weight heparin and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR0200596A BR0200596A (en) 2002-02-22 2002-02-22 Method of treatment by a combination of a tissue plasminogen activating variant (t-pa) and a low molecular weight heparin and use thereof

Publications (1)

Publication Number Publication Date
BR0200596A true BR0200596A (en) 2004-06-22

Family

ID=32476801

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0200596A BR0200596A (en) 2002-02-22 2002-02-22 Method of treatment by a combination of a tissue plasminogen activating variant (t-pa) and a low molecular weight heparin and use thereof

Country Status (1)

Country Link
BR (1) BR0200596A (en)

Similar Documents

Publication Publication Date Title
AU2002360488A8 (en) Methods and devices for detection and therapy of atheromatous plaque
BRPI0412411A (en) substituted tetrahydro-1h-pyrazol [3,4-c] pyridines, compositions containing them and use
ES2018729A6 (en) Tissue plasminogen activator having zymogenic or fibrin specific properties.
BR0317822A (en) Fluorochemical composition
DOP2002000438A (en) INHIBITORS OF DIPETIDIL PEPTIDASA BETA-AMINO HETEROCYCLIC FOR THE TREATMENT OR PREVENTION OF DIABETES
ATE314116T1 (en) USE OF ROXITHROMYCIN FOR PRODUCING A MEDICATION TO IMPROVE THE BIOLOGICAL AND ANTIVIRAL ACTIVITY OF PROTEASE INHIBITORS
DK1178958T3 (en) N-cyanomethylamides as protease inhibitors
MX9606386A (en) Agents affecting thrombosis hemostasis.
BRPI0509172A (en) at least one chemical entity, pharmaceutical composition, methods for treating a patient, inhibiting at least one enzyme using atp, and treating at least one disease, use of at least one chemical entity, and method for the manufacture of a medicament
DK623186D0 (en) POLYPEPTIDE WITH TISSUE PLASMINOGEN ACTIVATOR EFFECT
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
NO20051941L (en) Combination chemotherapy compositions and methods.
NO954722L (en) Peptide inhibitors with urokinase receptor activity
TR200003159T2 (en) Antipicornaviral compounds, their preparation and uses
EA200500782A1 (en) TREATMENT OF HEMORRHAGIC SHOCK
BRPI0508700A (en) use of sns-595, pharmaceutical composition and lyophilized powder
MY127938A (en) Combinatin therapy for treatment of partial responders or refractory depression
BR0010380A (en) Method, pharmaceutical composition, kit and use of a combination for prevention and treatment of various thromboembolic disorders and methods of treating thrombosis in mammals
CY1116164T1 (en) PRE-4-SULFATHATA N-ACETYLGALACTIN SAMINIS, METHODS OF THERAPEUTIC PURPOSES USING THE SOLE ENZYMES AND METHODS I KNOW
BR0200596A (en) Method of treatment by a combination of a tissue plasminogen activating variant (t-pa) and a low molecular weight heparin and use thereof
DE602005025772D1 (en) NEW CELL POPULATIONS AND ITS APPLICATIONS
AU8184301A (en) Inhibitors for the blood-clotting factor xa
Goldfarb et al. Degradation of glycoprotein and collagenous components of the basement membrane: studies with urokinase-type plasminogen activator, α-thrombin, and plasmin
BR0115534A (en) Isolated luciferases as well as their employment
MX9304070A (en) PIPERIDYLAMIDES, PIPERIDYL SULPHONAMIDES AND NOVEL PIPERIDYLSULFOXAMIDES AS INHIBITORS OF CHOLESTEROL BIOSYNTHESIS.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: GENENTECH, INC. (US) , BOEHRINGER INGELHEIM ITALIA

Free format text: ALTERADO O NOME DO SEGUNDO TITULAR DE: BOEHRINGER INGELHEIM PHARMA KG

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O ARTIGO 8O C/C 11E 8O C/C 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.